Old friends in new guise: Exploiting privileged structures for scaffold re-evolution/refining

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 6, 2014, Pages 536-553

  Song, Yu'Ning ^a   Chen, Wenmin ^a   Kang, Dongwei ^a   Zhang, Qingzhu ^a   Zhan, Peng ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Drug design; Drug repositioning; Privileged structure; Scaffold re evolution; Scaffold refining

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; 4 THIAZOLIDINONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ISOQUINOLINE DERIVATIVE; METAL CHELATE; PICOLINAMIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DERIVATIZATION; DRUG REPOSITIONING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TECHNOLOGY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; PROCEDURES; VIRUS; VIRUS DISEASES;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG REPOSITIONING; HUMANS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS DISEASES; VIRUSES;

EID: 84903710585     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666140122101631     Document Type: Article

References (109)

1. Tobinick, E.L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect., 2009, 22, 119-125
2. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3, 673-683 (Pubitemid 39173508)
3. Boguski, M.S.; Mandl, K.D.; Sukhatme, V.P. Drug discovery. Repurposing with a difference. Science, 2009, 324, 1394-1395
4. Wang, Z.Y.; Zhang, H.Y. Rational drug repositioning by medical genetics. Nat. Biotechnol., 2013, 31, 1080-1082
5. Jin, G.; Wong, S.T. Toward better drug repositioning: Prioritizing and integrating existing methods into efficient pipelines. Drug Discov. Today, 2013, pii: S1359-6446(13)00399-1, doi: 10.1016/j.drudis.2013.11.005. [Epub ahead of print]
6. Andronis, C.; Sharma, A.; Virvilis, V.; Deftereos, S.; Persidis, A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform., 2011, 12, 357-368
7. Dudley, J.T.; Deshpande, T.; Butte, A.J. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform., 2011, 12, 303-311
8. Haupt, V.J.; Schroeder, M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Brief Bioinform., 2011, 12, 312-326
9. Raju, T.N. The Nobel chronicles. 1988: James Whyte Black, (b 1924), Gertrude Elion (1918-99), and George H Hitchings (1905- 98). Lancet, 2000, 355, 1022
10. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246 (Pubitemid 19001640)
11. De Simone, R.W.; Currie, K.S.; Mitchell, S.A.; Darrow, J.W.; Pippin, D.A. Privileged structures: Applications in drug discovery. Comb. Chem. High Throughput Screen., 2004, 7, 473-494
12. Duarte, C.D.; Barreiro, E.J.; Fraga, C.A. Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini. Rev. Med. Chem., 2007, 7, 1108-1119 (Pubitemid 350200217)
13. Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem., 2006, 13, 65-85
14. Zhan, P.; Li, D.; Li, J.; Chen, X.; Liu, X. Benzimidazole heterocycle as a privileged scaffold in antiviral agents. Mini. Rev. Org. Chem., 2012, 9, 397-410
15. Curreli, F.; Zhang, H.; Zhang, X.; Pyatkin, I.; Victor, Z.; Altieri, A.; Debnath, A.K. Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid. Bioorg. Med. Chem., 2011, 19, 77-90
16. Debnath, A.K.; Zhang, H.; Curreli, F. Small molecule inhibitors of retroviral assembly and maturation. PCT Int. Appl. (2010), WO 2010017355 A2
17. Hamasaki, T.; Okamoto, M.; Baba, M. Identification of novel inhibitors of human immunodeficiency virus type 1 replication by in silico screening targeting Cyclin T1/Tat interaction. Antimicrob. Agents Chemother., 2013, 57, 1323-1331
18. Barreca, M.L.; De Luca, L.; Iraci, N.; Rao, A.; Ferro, S.; Maga, G.; Chimirri, A. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors. J. Chem. Inf. Model, 2007, 47, 557-562 (Pubitemid 46615957)
19. Hagiwara, K.; Murakami, T.; Xue, G.; Shimizu, Y.; Takeda, E.; Hashimoto, Y.; Honda, K.; Kondoh, Y.; Osada, H.; Tsunetsugu- Yokota, Y.; Aida, Y. Identification of a novel Vpr-binding compound that inhibits HIV-1 multiplication in macrophages by chemical array. Biochem. Biophys. Res. Commun., 2010, 403, 40- 45
20. Jiang, T.; Kuhen, K.L.; Wolff, K.; Yin, H.; Bieza, K.; Caldwell, J.; Bursulaya, B.; Wu, T.Y.; He, Y. Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. Bioorg. Med. Chem. Lett., 2006, 16, 2105-2108
21. Katritzky, A.R.; Tala, S.R.; Lu, H.; Vakulenko, A.V.; Chen, Q.Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A.K. Design, synthesis, and structure-activity relationship of a novel series of 2- aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors. J. Med. Chem., 2009, 52, 7631-7639
22. Jiang, S.; Tala, S.R.; Lu, H.; Abo-Dya, N.E.; Avan, I.; Gyanda, K.; Lu, L.; Katritzky, A.R.; Debnath, A.K. Design, synthesis, and biological activity of novel 5-((Arylfuran/1H-pyrrol-2- yl)methylene)-2-thioxo-3-(3-(trifluoromethyl) phenyl)thiazolidin-4- ones as HIV-1 fusion inhibitors targeting gp41. J. Med. Chem., 2011, 54, 572-579
23. Du, L.; Zhao, Y.; Chen, J.; Yang, L.; Zheng, Y.; Tang, Y.; Shen, X.; Jiang, H. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem. Biophys. Res. Commun., 2008, 375, 139-144
24. Wai, J.S.; Egbertson, M.S.; Payne, L.S.; Fisher, T.E.; Embrey, M.W.; Tran, L.O.; Melamed, J.Y.; Langford, H.M.; Guare, J.P.Jr.; Zhuang, L.; Grey, V.E.; Vacca, J.P.; Holloway, M.K.; Naylor- Olsen, A.M.; Hazuda, D.J.; Felock, P.J.; Wolfe, A.L.; Stillmock, K.A.; Schleif, W.A.; Gabryelski, L.J.; Young, S.D. 4-Aryl-2,4- dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J. Med. Chem., 2000, 43, 4923-4926
25. De Luca, L.; Gitto, R.; Christ, F.; Ferro, S.; De Grazia, S.; Morreale, F.; Debyser, Z.; Chimirri, A. 4-[1-(4-Fluorobenzyl)-4- hydroxy-1H-indol-3-yl]-2- hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. Antiviral. Res., 2011, 92, 102-107
26. Kirschberg, T.A.; Balakrishnan, M.; Squires, N.H.; Barnes, T.; Brendza, K.M.; Chen, X.; Eisenberg, E.J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J.K.; Wang, M.; Watkins, W.J.; Lansdon, E.B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural information. J. Med. Chem., 2009, 52, 5781-5784
27. Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V.G.; De Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem., 2004, 47, 14-17 (Pubitemid 38040485)
28. Baughman, B.M.; Jake Slavish, P.; DuBois, R.M.; Boyd, V.A.; White, S.W.; Webb, T.R. Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. ACS. Chem. Biol., 2012, 7, 526-534
29. Tumey, L.N.; Huck, B.; Gleason, E.; Wang, J.; Silver, D.; Brunden, K.; Boozer, S.; Rundlett, S.; Sherf, B.; Murphy, S.; Bailey, A.; Dent, T.; Leventhal, C.; Harrington, J.; Bennani, Y.L. The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4915-4918 (Pubitemid 39165594)
30. Billamboz, M.; Bailly, F.; Barreca, M.L.; De Luca, L.; Mouscadet, J.F.; Calmels, C.; Andréola, M.L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J. Med. Chem., 2008, 51, 7717-7730
31. Billamboz, M.; Bailly, F.; Lion, C.; Calmels, C.; Andréola, M.L.; Witvrouw, M.; Christ, F.; Debyser, Z.; De Luca, L.; Chimirri, A.; Cotelle, P. 2-hydroxyisoquinoline-1,3(2H,4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: influence of the alkylation of position 4. Eur. J. Med. Chem., 2011,46, 535-546
32. Billamboz, M.; Bailly, F.; Lion, C.; Touati, N.; Vezin, H.; Calmels, C.; Andréola, M.L.; Christ, F.; Debyser, Z.; Cotelle, P. Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: Discovery of a novel selective inhibitor of the ribonuclease H function. J. Med. Chem., 2011, 54,1812-1824
33. Suchaud, V.; Bailly, F.; Lion, C.; Tramontano, E.; Esposito, F.; Corona, A.; Christ, F.; Debyser, Z.; Cotelle, P. Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorg. Med. Chem. Lett., 2012, 22, 3988-3992
34. Desimmie, B.A.; Demeulemeester, J.; Suchaud, V.; Taltynov, O.; Billamboz, M.; Lion, C.; Bailly, F.; Strelkov, S.; Debyser, Z.; Cotelle, P.; Christ, F. 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance. ACS. Chem. Biol., 2013 Mar 21. [Epub ahead of print]
35. Billamboz, M.; Suchaud, V.; Bailly, F.; Lion, C.; Demeulemeester, J.; Calmels, C.; Andréola, M-L.; Christ, F.; Debyser, Z.; Cotelle, P. 4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 606-611
36. Chen, Y.L.; Tang, J.; Kesler, M.J.; Sham, Y.Y.; Vince, R.; Geraghty, R.J.; Wang, Z. The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3- diones as inhibitors of hepatitis C virus. Bioorg. Med. Chem., 2012, 20, 467-479
37. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Gonzalez Paz, O.; Hazuda, D.J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M.V.; Rowley, M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem., 2008, 51, 5843-5855
38. Lansdon, E.B.; Liu, Q.; Leavitt, S.A.; Balakrishnan, M.; Perry, J.K.; Lancaster-Moyer, C.; Kutty, N.; Liu, X.; Squires, N.H.; Watkins, W.J.; Kirschberg, T.A. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV- 1 RNase H inhibitors. Antimicrob. Agents Chemother., 2011, 55, 2905-2915
39. Koch, U.; Attenni, B.; Malancona, S.; Colarusso, S.; Conte, I.; Di Filippo, M.; Harper, S.; Pacini, B.; Giomini, C.; Thomas, S.; Incitti, I.; Tomei, L.; De Francesco, R.; Altamura S.; Matassa, V.G.; Narjes, F. 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: Discovery, SAR, modeling, and mutagenesis. J. Med. Chem., 2006, 49, 1693- 1705
40. Johnson, T.W.; Tanis, S.P.; Butler, S.L.; Dalvie, D.; Delisle, D.M.; Dress, K.R.; Flahive, E.J.; Hu, Q.; Kuehler, J.E.; Kuki, A.; Liu, W.; McClellan, G.A.; Peng, Q.; Plewe, M.B.; Richardson, P.F.; Smith, G.L.; Solowiej, J.; Tran, K.T.; Wang, H.; Yu, X.; Zhang, J.; Zhu, H. Design and synthesis of novel N-hydroxydihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors. J. Med. Chem., 2011, 54, 3393-3417
41. Pryde, D.C.; Webster, Rob.; Butler, S. L.; Murray, E.J.; Whitby, K.; Pickford, C.; Westby, M.; Palmer, M.J.; Bull, D. J.; Vuong, H.; Blakemore, D.C.; Stead, D.; Ashcroft, C.; Gardner, I.; Bru, C.; Cheung, W.-Y.; Roberts, I. O.; Morton, J.; Bissell, R.A. Discovery of an HIV Integrase inhibitor with an excellent resistance profile. Med. Chem. Commun., 2013, 4, 709-719
42. Dress, K.R.; Johnson, T.W.; Plewe, M.B.; Tanis, S.P.; Zhu, H. tetrahydropyrrolonaphthyridinones and related compounds as inhibitors of the HIV integrase enzyme and their preparation. From PCT Int. Appl. (2007), WO 2007042883A1 20070419
43. Stranix, B.; Beaulieu, F.; Bouchard, J-E.; Milot, G.; Zhigang, W.; Ruel, R. Pyridoxine derivatives as HIV integrase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of HIV infection and AIDS. PCT Int. Appl. (2009), WO 2009146555 A1 20091210
44. Benenato, K.E.; Choy, A.L.; Hale, M.R.; Hill, P.; Marone, V.; Miller, Mw. Preparation of hydroxamic acid derivatives as gramnegative antibacterial agents. PCT Int. Appl. (2010), WO 2010100475 A1 20100910
45. Su, H.P.; Yan, Y.; Prasad, G.S.; Smith, R.F.; Daniels, C.L.; Abeywickrema, P.D.; Reid, J.C.; Loughran, H.M.; Kornienko, M.; Sharma, S.; Grobler, J.A.; Xu, B.; Sardana, V.; Allison, T.J.; Williams, P.D.; Darke, P.L.; Hazuda, D.J.; Munshi, S. Structural basis for the inhibition of RNaseH activity of HIV-1 Reverse Transcriptase by RNaseH active site-directed inhibitors. J. Virol., 2010, 84, 7625-7633
46. Williams, P.D.; Venkatraman, S.; Langford, H.M.;; Kim, B.; Booth, T.M.; Grobler, J.A.; Staas, D.; Ruzek, R.D.; Embrey, M.W.; Wiscount, C.M.; Lyle, T.A. 1-Hydroxy naphthyridine compounds as anti-HIV agents. WO2008010964A1; Publication Date:24.01.2008
47. Williams, P.D.; Venkatraman, S.; Langford, H.M.;; Kim, B.; Booth, T.M.; Grobler, J.A.; Staas, D.; Ruzek, R.D.; Embrey, M.W.; Wiscount, C.M.; Lyle, T.A. 1-Hydroxy naphthyridine compounds as anti-HIV agents. US2010056516A1. 2010-3-4
48. Tumey, L.N.; Bom, D.; Huck, B.; Gleason, E.; Wang, J.; Silver, D.; Brunden, K.; Boozer, S.; Rundlett, S.; Sherf, B.; Murphy, S.; Dent, T.; Leventhal, C.; Bailey, A.; Harrington J.; Bennani YL. The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 277-281 (Pubitemid 39647135)
49. Tumey, L.N.; Bennani, Y.; Huck, B.; Bom, D.C. Preparation of fused 3-hydroxypyrimidine-2,4-diones as inhibitors of flap endonuclease. From PCT Int. Appl. (2006), WO 2006014647 A2 20060209
50. Didierjean, J.; Isel, C.; Querré F.; Mouscadet, J.F.; Aubertin, A.M.; Valnot, J.Y.; Piettre, S.R.; Marquet, R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother., 2005, 49, 4884-4894
51. 2+-dependent HIV-1 RNase H construct for drug screening. Antimicrob. Agents Chemother., 2011, 55, 4735- 4741
52. Iwatsuki, M.; Takada, S.; Mori, M.; Ishiyama, A.; Namatame, M.; Nishihara-Tsukashima, A.; Nonaka, K.; Masuma, R.; Otoguro, K.; Shiomi, K.; Omura, S. In vitro and in vivo antimalarial activity of puberulic acid and its new analogs, viticolins A-C, produced by Penicillium sp. FKI-4410. J. Antibiot (Tokyo)., 2011, 64, 183-188
53. Oblak, E.Z.; Bolstad, E.S.; Ononye, S.N.; Priestley, N.D.; Hadden, M.K.; Wright, D.L. The furan route to tropolones: Probing the antiproliferative effects of β-thujaplicin analogs. Org. Biomol. Chem., 2012, 10, 8597-8604
54. Koufaki, M.; Theodorou, E.; Alexi, X.; Nikoloudaki, F.; Alexis, M.N. Synthesis of tropolone derivatives and evaluation of their in vitro neuroprotective activity. Eur. J. Med. Chem., 2010, 45, 1107- 1112
55. Ononye, S.N.; VanHeyst, M.D.; Oblak, E.Z.; Zhou, W.; Ammar, M.; Anderson, A.C.; Wright, D.L. Tropolones As Lead-Like Natural Products: The Development of Potent and Selective Histone Deacetylase Inhibitors. ACS Med. Chem. Lett.,, 2013, on line
56. Kawasuji, T.; Johns, B.A.; Yoshida, H.; Weatherhead, J.G.; Akiyama, T.; Taishi, T.; Taoda, Y.; Mikamiyama-Iwata, M.; Murai, H.; Kiyama, R.; Fuji, M.; Tanimoto, N.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Garvey, E.P.; Fujiwara, T. Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles. J. Med. Chem., 2013 Jan 22. [Epub ahead of print]
57. Agrawal, A.; de Oliveira, C.A.; Cheng, Y.; Jacobsen, J.A.; McCammon, J.A.; Cohen, S.M. Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. J. Med. Chem., 2009, 52, 1063-1074
58. Zhan, P.; Chen, X.; Li, D.; Fang, Z.; De Clercq, E.; Liu, X. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and impliations for drug design. Med. Res. Rev., 2013, 33 Suppl 1, E1- E72
59. Song, Y.; Zhan, P.; Zhang, Q.; Liu, X. Privileged scaffolds or promiscuous binders: A glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Des., 2013, 19, 1528-1548
60. Editor(s): Richard, A.W, Frederick, G. Kinase Drug Discovery. Chapter 1. The Kinome and its Impact on Medicinal Chemistry. Drewry, D.H.; Bamborough, P.; Schneider, K.; Smith, G.K. ISBN: 978-1-84973-174-4; eISBN: 978-1-84973-355-7. DOI:10.1039/9781849733557-00001
61. Mekouar, K.; Mouscadet, J.F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré D.; Auclair, C.; d'Angelo, J. Styrylquinoline derivatives: A new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem., 1998, 41, 2846-2857
62. Cohen, S.M.; Agrawal, A.; Desoto, J.; Pommier, Y.; Maddali, K. Preparation of raltegravir-chelator derivatives as HIV integrase inhibitors PCT Int. Appl. (2012), WO 2012106534 A2, 20120809
63. Serrao, E.; Debnath, B.; Otake, H.; Kuang, Y.; Christ, F.; Debyser, Z.; Neamati, N. Fragment-Based Discovery of 8-Hydroxyquinoline Inhibitors of the HIV-1 Integrase-Lens Epithelium-Derived Growth Factor/p75 (IN-LEDGF/p75) Interaction. J. Med. Chem., 2013, 56, 2311-2322
64. Chan, S.H.; Chui, C.H.; Chan, S.W.; Kok, Stanton H.L.; Chan, D.; Tsoi, Miriam Y.T.; Leung, Polly H.M.; Lam, Alfred K.Y.; Chan, Albert S.C.; Lam, K.H.; Tang, Johnny C.O. Synthesis of 8- Hydroxyquinoline Derivatives as Novel Antitumor Agents. ACS Med. Chem. Lett., 2013, 4, 170-174
65. Silvestri, R.; Artico, M. Indolyl aryl sulfones (IASs): Development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants. Curr. Pharm. Des., 2005, 11, 3779- 806 (Pubitemid 41632254)
66. Magedov, I.V.; Lefranc, F.; Frolova, L.V.; Banuls, L.M.; Peretti, A.S.; Rogelj, S.; Mathieu, V.; Kiss, R.; Kornienko, A. Antiproliferative activity of 2,3-disubstituted indoles toward apoptosis-resistant cancers cells. Bioorg. Med. Chem. Lett., 2013, 23, 3277-3282
67. La Regina, G.; Bai, R.; Rensen, W.M.; Di Cesare, E.; Coluccia, A.; Piscitelli, F.; Famiglini, V.; Reggio, A.; Nalli, M.; Pelliccia, S.; Da Pozzo, E.; Costa, B.; Granata, I.; Porta, A.; Maresca, B.; Soriani, A.; Iannitto, M.L.; Santoni, A.; Li, J.; Miranda Cona, M.; Chen, F.; Ni, Y.; Brancale, A.; Dondio, G.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Martini, C.; Hamel, E.; Lavia, P.; Novellino, E.; Silvestri, R. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J. Med. Chem., 2013, 56, 123-149
68. Rawal, R.K.; Prabhakar, Y.S.; Katti, S.B.; De Clercq, E. 2-(Aryl)- 3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors. Bioorg. Med. Chem., 2005, 13, 6771-6776 (Pubitemid 41571222)
69. Rawal, R.K.; Katti, S.B.; Kaushik-Basu, N.; Arora, P.; Pan, Z. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNAdependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4- one derivatives. Bioorg. Med. Chem. Lett., 2008, 18, 6110-6114
70. Goel, B.; Ram, T.; Tyagi, R.; Bansal, E.; Kumar, A.; Mukherjee, D.; Sinha, J.N. 2-Substituted-3-(4-bromo-2-carboxyphenyl)-5- methyl-4- thiazolidinones as potential anti-inflammatory agents. Eur. J. Med. Chem., 1999, 34, 265-269
71. Sala, M.; Chimento, A.; Saturnino, C.; Gomez-Monterrey, I.M.; Musella, S.; Bertamino, A.; Milite, C.; Sinicropi, M.S.; Caruso, A.; Sirianni, R.; Tortorella, P.; Novellino, E.; Campiglia, P.; Pezzi, V. Synthesis and cytotoxic activity evaluation of 2,3-thiazolidin-4-one derivatives on human breast cancer cell lines. Bioorg. Med. Chem. Lett., 2013, pii: S0960-894X(13)00772-5
72. Suthar, S.K.; Bansal, S.; Lohan, S.; Modak, V.; Chaudhary, A.; Tiwari, A. Design and synthesis of novel 4-(4-oxo-2-arylthiazolidin-3- yl)benzenesulfonamides as selective inhibitors of carbonic anhydrase IX over I and II with potential anticancer activity. Eur. J, Med, Chem., 2013, 66C, 372-379
73. Polanski, J.; Kurczyk, A.; Bak, A.; Musiol, R. Privileged structures - dream or reality: Preferential organization of azanaphthalene scaffold. Curr. Med. Chem., 2012, 19, 1921-1945
74. Zhang, Y.; Fu-Yang, Lin.; Li, K.; Zhu, W.; Liu, Y.L.; Cao, R.; Pang, R.; Lee, E.; Axelson, J.; Hensler, M.; Wang, K.; Molohon, K.J.; Wang, Y.; Mitchell, D.A.; Nizet, V.; Oldfield, E. HIV-1 integrase inhibitor-inspired antibacterials targeting isoprenoid biosynthesis. ACS. Med. Chem. Lett., 2012, 3, 402-406
75. Zhu, W.; Zhang, Y.; Sinko, W.; Hensler, M.E.; Olson, J.; Molohon, K.J.; Lindert, S.; Cao, R.; Li, K.; Wang, K.; Wang, Y.; Liu, Y.L.; Sankovsky, A.; de Oliveira, C.A.; Mitchell, D.A.; Nizet, V.; McCammon, J.A.; Oldfield, E. Antibacterial drug leads targeting isoprenoid biosynthesis. Proc. Natl. Acad. Sci. USA., 2013, 110, 123-128
76. Deore, R.R.; Chen, G.S.; Chen, C.S.; Chang, P.T.; Chuang, M.H.; Chern, T.R.; Wang, H.C.; Chern, J.W. 2-Hydroxy-1-oxo-1,2- dihydroisoquinoline-3- carboxylic acid with inbuilt β-N-hydroxy-γ- keto-acid pharmacophore as HCV NS5B polymerase inhibitors. Curr. Med. Chem., 2012, 19, 613-624
77. Jones, E.D.; Vandegraaff, N.; Le, G.; Choi, N.; Issa, W.; Macfarlane, K.; Thienthong, N.; Winfield, L.J.; Coates, J.A.; Lu, L.; Li, X.; Feng, X.; Yu, C.; Rhodes, D.I.; Deadman, JJ. Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold. Bioorg. Med. Chem. Lett., 2010, 20, 5913-5917
78. Deore, R.R.; Chen, G.S.; Chang, P.T.; Chern, T.R.; Lai, S.Y.; Chuang, M.H.; Lin, J.H.; Kung, F.L.; Chen, C.S.; Chiou, C.T.; Chern, J.W. Discovery of N-arylalkyl-3-hydroxy-4-oxo-3,4- dihydroquinazolin-2-carboxamide derivatives as HCV NS5B polymerase inhibitors. ChemMedChem, 2012, 7, 850-860
79. Zhan, P.; Liu, X. Rationally designed multitarget anti-HIV agents. Curr. Med. Chem., 2013, 20, 1743-58
80. Zhan, P.; Liu, X. Designed multiple ligands: An emerging anti-HIV drug discovery paradigm. Curr. Pharm. Des., 2009, 15, 1893-1917
81. Tang, J.; Maddali, K.; Dreis, C.D.; Sham, Y.Y.; Vince, R.; Pommier, Y.; Wang, Z. N-3 Hydroxylation of pyrimidine-2,4- diones yields dual inhibitors of HIV reverse transcriptase and integrase. ACS Med. Chem. Lett., 2011, 2, 63-67
82. Tang, J.; Maddali, K.; Metifiot, M.; Sham, Y.Y.; Vince, R.; Pommier, Y.; Wang, Z. 3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase. J. Med. Chem., 2011, 54, 2282-2292
83. Tang, J.; Maddali, K.; Dreis, C.D.; Sham, Y.Y.; Vince, R.; Pommier, Y.; Wang, Z. 6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. Bioorg. Med. Chem. Lett., 2011, 21, 2400-2402
84. Tian, X.; Qin, B.; Lu, H.; Lai, W.; Jiang, S.; Lee, K.H.; Chen, C.H.; Xie, L. Discovery of diarylpyridine derivatives as novel nonnucleoside HIV-1 reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5482-5485
85. Wang, X.F.; Tian, X.T.; Ohkoshi, E.; Qin, B.; Liu, Y.N.; Wu, P.C.; Hour, M.J.; Hung, H.Y.; Qian, K.; Huang, R.; Bastow, K.F.; Janzen, W.P.; Jin, J.; Morris- Natschke, S.L.; Lee, K.H.; Xie, L. Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents. Bioorg. Med. Chem. Lett., 2012, 22, 6224-6228
86. Wang, X.F.; Ohkoshi, E.; Wang, S.B.; Hamel, E.; Bastow, K.F.; Morris- Natschke, S.L.; Lee, K.H.; Xie, L. Synthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors. Bioorg. Med. Chem., 2013, 21, 632-642
87. Wang, X.F.; Wang, S.B.; Ohkoshi, E.; Wang, L.T.; Hamel, E.; Qian, K.; Morris-Natschke, S.L.; Lee, K.H.; Xie, L. N-Aryl-6-methoxy-1,2,3,4- tetrahydroquinolines: A Novel Class of Antitumor Agents Targeting the Colchicine Site on Tubulin. Eur. J. Med. Chem., 2013, 67, 196-207
88. Hazuda, D.J.; Anthony, N.J.; Gomez, R.P.; Jolly, S.M.; Wai, J.S.; Zhuang, L.; Fisher, T.E.; Embrey, M.; Guare, J.P.Jr.; Egbertson, M.S.; Vacca, J.P.; Huff, J.R.; Felock, P.J.; Witmer, M.V.; Stillmock, K.A.; Danovich, R.; Grobler, J.; Miller, M.D.; Espeseth, A.S.; Jin, L.; Chen, I.W.; Lin, J.H.; Kassahun, K.; Ellis, J.D.; Wong, B.K.; Xu, W.; Pearson, P.G.; Schleif, W.A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M.K.; Young, S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA, 2004, 101, 11233-11238
89. Zartman, C.B.; Bell, I.M.; Gallicchio, S.N.; Graham, S.L.; Kane, S.A.; Mallee, J.J.; Rutledge, R.Z.; Salvatore, C.A.; Vacca, J.P.; Williams, T.M. Identification of a novel RAMP independent CGRP receptor antagonist. Bioorg. Med. Chem. Lett., 2011, 21, 6705- 6708
90. Zeng, L.F.; Wang, Y.; Kazemi, R.; Xu, S.; Xu, Z.L.; Sanchez, T.W.; Yang, L.M.; Debnath, B.; Odde, S.; Xie, H.; Zheng, Y.T.; Ding, J.; Neamati, N.; Long, Y.Q. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7- carboxamide as a promising scaffold with drug-like properties. J. Med. Chem., 2012, 55, 9492-9509
91. Wang, Y.; Xu, Z.L.; Ai, J.; Peng, X.; Lin, J.P.; Ji, Y.C.; Geng, M.Y.; Long, Y.Q. Investigation on the 1,6-naphthyridine motif: Discovery and SAR study of 1Himidazo[ 4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors. Org. Biomol. Chem., 2013, 11, 1545-1562
92. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5- alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. J. Med. Chem., 2001, 44, 2544-2554
93. Ragno, R.; Mai, A.; Sbardella, G.; Artico, M.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; La Colla, P. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1- (2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem., 2004, 47, 928-934
94. Bartolini, S.; Mai, A.; Artico, M.; Paesano, N.; Rotili, D.; Spadafora, C.; Sbardella, G. 6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. J. Med. Chem., 2005, 48, 6776-6778
95. Williams, P.D.; Staas, D.D.; Venkatraman, S.; Loughran, H.M.; Ruzek, R.D.; Booth, T.M.; Lyle, T.A.; Wai, J.S.; Vacca, J.P.; Feuston, B.P.; Ecto, L.T.; Flynn, J.A.; Distefano, D.J.; Hazuda, D.J.; Bahnck, C.M.; Himmelberger, A.L.; Dornadula, G.; Hrin, R.C.; Stillmock, K.A.; Witmer, M.V.; Miller, M.D.; Grobler, J.A. Potent and selective HIV-1 ribonuclease H inhibitors based on a 1- hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg. Med. Chem. Lett., 2010, 20, 6754-6757
96. Kirby, K.A.; Marchand, B.; Ong, Y.T.; Ndongwe, T.P.; Hachiya, A.; Michailidis, E.; Leslie, M.D.; Sietsema, D.V.; Fetterly, T.L.; Dorst, C.A.; Singh, K.; Wang, Z.; Parniak, M.A.; Sarafianos, S.G. Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob. Agents Chemother., 2012, 56, 2048- 2061
97. Tavis, J.E.; Cheng, X.; Hu, Y.; Totten, M.; Cao, F.; Michailidis, E.; Aurora, R.; Meyers, M.J.; Jacobsen, E.J.; Parniak, M.A.; Sarafianos, S.G. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS. Pathog., 2013, 9, e1003125
98. Hu, Y.; Cheng, X.; Cao, F.; Huang, A.; Tavis, J.E. β- Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral. Res., 2013, 99, 221-229
99. Moyle G.; Boffito M.; Stoehr A.; Rieger A.; Shen Z.; Manhard K.; Sheedy B.; Hingorani V.; Raney A.; Nguyen M.; Nguyen T.; Ong V.; Yeh LT.; Quart B.Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1- positive, antiretroviral-naive subjects. Antimicrob. Agents Chemother., 2010, 54, 3170-3178
100. Ardea home page. [updated 2012; cited 2013 Jun 29]. Available from: http://www.ardeabio.com/development-pipeline/gout.htm
101. Pema, K.M. Lesinurad sodium. Solute carrier family 22 member 12 (URAT1) inhibitor, uricosuric, treatment of gout. Drugs of the Future, 2011, 36, 875-880
102. Vicenzi, E.; Liò P.; Poli, G. The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics, 2013, 3, 18-25
103. Richard, C.L.; Blay, J. CXCR4 in cancer and its regulation by PPARgamma. PPAR. Res., 2008, 2008, 769413
104. Ochoa-Callejero, L.; Pérez-Martínez, L.; Rubio-Mediavilla, S.; Oteo, J.A.; Martínez, A.; Blanco, J.R. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS. One, 2013, 8, e53992
105. Alonzo, F 3rd.; Kozhaya, L.; Rawlings, S.A.; Reyes-Robles, T.; DuMont, A.L.; Myszka, D.G.; Landau, N.R.; Unutmaz, D.; Torres, V.J. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature, 2013, 493, 51-55
106. Song, Y.; Zhan, P.; Liu, X. Heterocycle-thioacetic acid motif: A privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Des., 2013, 19, 7141- 7154;
107. Song, Y.; Fang, Z.; Zhan, P.; Liu, X. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 Update. Curr. Med. Chem., 2013, 21, 329-355
108. Li, Y.Y.; An, J.; Jones, S.J. A large-scale computational approach to drug repositioning. Genome Inform., 2006, 17, 239-247
109. Daminelli, S.; Haupt, V.J.; Reimann, M.; Schroeder, M. Drug repositioning through incomplete bi-cliques in an integrated drugtarget- disease network. Integr. Biol (Camb)., 2012, 4, 778-788